Novartis Oncology的动态

Phase 3 ASC4FIRST Trial: Asciminib proved more effective and safer than other treatments for newly diagnosed chronic Myelogenous Leukemia, with most patients still on treatment after 48 weeks. At VieCure, we embrace innovations like CAR T-cell therapy and Asciminib by integrating them into our clinical decision support platform. We ensure that oncologists have access to the latest advancements, always putting patient care first. #VieCure #PrecisionOncologyhttps://lnkd.in/gV7AVAQ5

September 1st?marks World CLL Day.?CLL (chronic lymphocytic leukemia) is the most common form of leukemia, yet it is still rare with about 600-1000 patients receiving the diagnosis each year in Belgium.? ? At AstraZeneca, we are dedicated to addressing the needs of patients by providing a platform that brings information and patients together to ensure support, information and connection.? ?? https://lnkd.in/gJ3cGcdU ?? https://lnkd.in/gvGyf2YH ? Together, we can make a difference in the lives of those affected by CLL. AZ BeLux,? from hope, to impact. ? #WCLLD24 #LetsLevelUp #CLL #FromHopeToImpact https://www.wclld.org/

More than 1000 people are diagnosed with #leukemia every day; however, the nonspecific signs and symptoms make it difficult to recognize. On #WorldLeukemiaDay, join Kura Oncology and Acute Leukemia Advocates Network in raising awareness of the signs and symptoms of this condition. By helping more people get diagnosed earlier, we can help reduce the number of preventable deaths and improve outcomes. See the most common symptoms and #BeLeukemiaAware: https://bit.ly/3MuHAFi #WLD24 Learn more about Kura’s commitment to helping patients with acute leukemia lead better, longer lives: https://bit.ly/4dPuwGs

Leukemia symptoms can vary depending on the type and stage of the disease, and in some cases, they may not be noticeable until the condition has progressed. Common symptoms of leukemia include persistent fatigue that doesn't improve with rest, easy bruising, and prolonged bleeding. Consult Our Medical Oncologist. Dr. Sravan Kumar Dubasi Medical and hemato Oncologist Book appointment: 90528 48508 #Drsravankumardubasi #medicalandhematooncologist #oncologist #pancreaticcancer #hematooncologist #Services #stomachcancer #lungcancer #livercancer #cervicalcancer #breastcancer #gallbladdercancer #pancreaticcancer #prostatecancer #uterinecancer. Follow us on: https://lnkd.in/gAi2Dkh8

Young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) have seen improved prognosis with pediatric-inspired chemotherapy like pegaspargase. However, pegaspargase therapy poses thrombotic risks. Management strategies, such as AT III replacement and cryoprecipitate therapy, are being studied to address these complications. Learn about AT III monitoring and replacement in the latest Oncolytics Today.?https://lnkd.in/e6cJth-i

#News for #Investors and #Media: our BTK inhibitor is now reimbursed for eligible patients with chronic lymphocytic leukemia in Lithuania, where reimbursement timelines are markedly longer compared to other European countries according to the W.A.I.T Indicator report published by IQVIA. This milestone is a testament to our commitment to expanding access to innovative medicines for patients around the world. #CLL #PatientsFirst ?

The power of science

"?? On World Leukemia Day, let's amplify the importance of early detection. ?? With the Hemavision??-28Q/7Q Leukemia Kit, we're empowering healthcare professionals ?? to diagnose and treat leukemia sooner, giving patients a fighting chance. ??? Early diagnosis saves lives—together, we can make a difference. ???? #WorldLeukemiaDay #EarlyDetection #Hemavision??-28Q/7Q #GenetixBiotechAsiaPvtLtd #HealthcareInnovation #FightLeukemia "

Guidelines for Venetoclax dosing in AML A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients https://lnkd.in/de8ZVUmZ

I'm excited to share another impactful study, titled "Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens", published in Haematologica Journal! This study from Universit?tsklinikum Schleswig-Holstein explores a crucial aspect of acute myeloid leukemia treatment. ?? Although immediate treatment initiation is standard for newly diagnosed AML, this study using TriNetX suggests that deferring therapy to assess comorbidities/risk factors does not negatively impact survival. Analysis of 855 patients (138 from SAL-registry and 717 from TriNetX) showed no significant survival difference between early and delayed treatment groups. Delaying venetoclax-based therapy can be a safe option with proper clinical monitoring. Read the full study here: https://lnkd.in/d6EfFNtr A big thank you to Dr. David Baden for his hard work and dedication! #LeukemiaResearch #Venetoclax #CancerResearch